▴ Bicalutamide is an oral, once-daily nonsteroidal antiandrogen. Its efficacy in localised or locally advanced prostate cancer is currently being investigated as part of the Early Prostate Cancer (EPC) programme.
▴ In the EPC programme, bicalutamide 150 mg/day, as an adjunct to radiotherapy, radical prostatectomy or watchful waiting, significantly reduced the risk of objective disease progression, the incidence of bone metastases and the risk of prostate specific antigen progression compared with placebo (p < 0.0001 for all three parameters) after a median follow-up of 3 years. Survival data are currently immature, with an overall mortality rate of 6% in both treatment arms.
▴ In two nonblind, randomised trials, bicalutamide 150 mg/day monotherapy was as effective as medical or surgical castration in terms of overall survival in patients with locally advanced nonmetastatic prostate cancer. After a median follow-up of 6.3 years, median survival was 63.5 and 69.9 months for bicalutamide and castration, respectively; time to disease progression was also similar between treatment groups. Bicalutamide recipients reported a significantly smaller loss in sexual interest and a better physical capacity than recipients of castration (p ≤0.05 for both parameters).
▴ Bicalutamide is well tolerated in studies of up to 6.3 years’ duration.
KeywordsProstate Cancer Bone Mineral Density Androgen Receptor Radical Prostatectomy Advanced Prostate Cancer
- 1.American Cancer Society. 2000 facts and figures. Selected cancers: prostate [online]. Available from URL: http://www.cancer.org/statistics/cff2000/selectedcancers.html [Accessed 2002 May 30]. 2000
- 4.National Cancer Institute. Prostate Cancer: Treatment. Stage Information [online]. Available from URL: http://www.cancer.gov [Accessed 2002 Jun 10].
- 12.Casodex international prescribing information. Cheshire, UK: Astra Zeneca, 2000 MarGoogle Scholar
- 20.Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51(3): 389–96PubMedCrossRefGoogle Scholar
- 22.See W, McLeod DG, Wirth M, et al. Bicalutamide (Casodex) 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer [abstract]. J Urol 2001 May; 165 (Abstr. Suppl.): 389Google Scholar
- 23.Iversen P, Tammela TLJ, Vaage S, et al. A randomised comparison of bicalutamide (‘Casodex”) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002 Sep; 42(3): 204–11Google Scholar
- 27.Tyrell CJ, Blake GM, Iversen P, et al. Casodex may preserve bone mineral density of patients with advanced prostate cancer [abstract]. Br J Urol Int 2000; 86 Suppl. 3: M6.1.09Google Scholar
- 28.Sieber PR, Keiller DL, Kahnoski RJ, et al. Bone mineral density is maintained during bicalutamide (‘Casodex‘) treatment [abstract no 783][online]. Available from URL: http://www.asco.org [Accessed 2002 Oct 9]
- 29.AstraZeneca. Casodex 150 International Data Sheet[online]. Available from http://www.prostateline.com [Accessed 2002 June 6]
- 30.Casodex prostate cancer monotherapy survival is similar to castration — U.K. FDC Pink 1999 Jul 5; 61: 15Google Scholar
- 31.AstraZeneca. AstraZeneca receives FDA priority review for CASODEX (R) 150mg, for early stage prostate cancer. Media Rel 2002 Feb 20, 2Google Scholar